{"name":"Theravance Biopharma","slug":"theravance","ticker":"TBPH","exchange":"NASDAQ","domain":"theravance.com","description":"Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.","hq":"South San Francisco, CA","founded":0,"employees":"90","ceo":"Rick E Winningham","sector":"Respiratory / Neurology","stockPrice":16.62,"stockChange":-0.05,"stockChangePercent":-0.3,"marketCap":"$857M","metrics":{"revenue":109775000,"revenueGrowth":15,"grossMargin":71,"rdSpend":37414000,"netIncome":105895000,"cash":394665984,"dividendYield":0,"peRatio":7.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"YUPELRI patent cliff ($143.8M at risk)","drug":"YUPELRI","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"REVEFIRDEN patent cliff ($20.8M at risk)","drug":"REVEFIRDEN","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TD-1607","genericName":"TD-1607","slug":"td-1607","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TD-1607","genericName":"TD-1607","slug":"td-1607","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Theravance Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Theravance Biopharma reported fourth quarter and full year 2023 financial results, with revenue of $143.8 million and a net loss of $144.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Theravance Biopharma Announces Collaboration with GSK to Develop Novel Respiratory Therapies","summary":"Theravance Biopharma announced a collaboration with GSK to develop novel respiratory therapies, including a next-generation LAMA/LABA combination.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves YUPELRI for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)","summary":"The FDA approved YUPELRI for the treatment of COPD, expanding the product's indication to include patients with a history of asthma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaGZpc2lURHBrWG80eGYtS1RPLThVQmZOWW5aajlyTnpsLTNyM2RWUDJLWUJyRVZBRmxKN0tseEtEc1ZORWNtNVRtQzZrWXBkVjNtME1TUkRUaXJZVU91M1FNOS1IeDd5ZTJKbmh4ZUs1a1d4ZW9tdU04RzZNNzFlOWNPRDZMai1NWFB5bzVGQm9pVmJ6VlRYZ1Zvc0NwMF9IcnBFY3IxUWF1c3hYMS1GTw?oc=5","date":"2026-04-06","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drd9IBY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drdw?oc=5","date":"2026-04-06","type":"pipeline","source":"Bitget","summary":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget","headline":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNQ1pZNzh2X3pJR29iMm9sd2hYOGhEYWtndFVsaEpiV0pvNVpDYzdITFcwLXFyQmY3WnptZ05rYnZtN3c5Z2N4ZnZlYW9XbllBdDNCX0xOYVJkcjQ5RjIxdkFUOFM1TDVxMFIwU2czQ2s2NnU3dGg3WllPaUM1Tko1WHJSTFhDYUhKdWtYSFV1QWdjcDRnSnJmTUdWYXlkREt0TC1kVkh4TV9TbkhGWU5fcTFENA?oc=5","date":"2026-03-30","type":"patent","source":"Stock Titan","summary":"Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement - Stock Titan","headline":"Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNS0hET1Q4NzJUOTV0NkpmVXdKZzNWTGZRN1ltTmo2YnBOU0M5cXpIX0FjM3Bwc0xjN2hkUmhyeXA1VS1neWZXODhCQmlXQWxXSHNBWllwZEY5VkxiWVZGNXprbURMRWRWVGJZTnpxdVY5U3pOLXdTRmhpeDNtRk9ZQXBKV1NSLS15V0QzQl9xUlIwZW01U2FjNkMtVFRGZkdGUjk1aHE4OGItNkRCUTNCdmRR?oc=5","date":"2026-03-04","type":"trial","source":"TradingView","summary":"TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - TradingView","headline":"TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOSVZId0VidFhPZzQtanhNUG1CNmF3YzZ1SXYtalNMZGxYY0c4ZTU0S2NfN2stRENKckZKYUlEQmdDd1FpeUI4a0gyS0ZBeGpIVzJwOTAwdDZtdkFKVTZvTllCUE0yRW1FdGpKczUyb2psRzh5SVIzSFN1SlFVT05wZ0VaVmpNRXZyRC1uQ1dOQ1VEMG5FRDI0TGdMWW5yZw?oc=5","date":"2026-03-04","type":"pipeline","source":"The Pharma Letter","summary":"Share tumbles and jobs to go after Theravance failure - The Pharma Letter","headline":"Share tumbles and jobs to go after Theravance failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQcmFHY2x4NUo0OGdYcHZabmlfdFROdXhPT3JLcFk1U2M3NUpMRl91bV9KUDRSSTMxTHh2eG9mTDE5akhCSU04VUtRX1Byd085a0J2eVQ3bFdWVTVaLUZhQThKZ1lfbFUxYmVYQ0VJazN5MU5TLUJFeGdLRmp2UEEyYWZpamlQUlVqemt5VU56YTZ5SUFDNHFaY2Qxc3R1NzhSS2lKZlVrQk1oMmYwUXlLRW11UQ?oc=5","date":"2026-03-03","type":"trial","source":"Stock Titan","summary":"Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review - Stock Titan","headline":"Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review","sentiment":"negative"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-04","type":"pipeline","source":"simplywall.st","summary":"Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile? - simplywall.st","headline":"Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"earnings","source":"simplywall.st","summary":"Revenues Not Telling The Story For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Shares Rise 32% - simplywall.st","headline":"Revenues Not Telling The Story For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Shares Rise 32%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNNEFEN1QxcV9sN3V3M1ZQTEptczk4QmVOY2NVTk1hQi14SmZmRl9XakVQdGhTblBRNGg0QzNJbF91RURGc2JYOVozMFExRnZVN3hXTVB5UGlDOGJ5QlhCUjRTUjlQMHNDTnA2VjhybmZZQkxnUmdjN1ZrZy1SaXFROFhnSmo?oc=5","date":"2025-08-13","type":"earnings","source":"Yahoo Finance","summary":"Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance","headline":"Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...","sentiment":"positive"}],"patents":[{"drugName":"YUPELRI","drugSlug":"glycopyrrolate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":143800000},{"drugName":"REVEFIRDEN","drugSlug":"revefenacin","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":20800000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","GSK","Novartis"],"therapeuticFocus":["Respiratory","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":15386000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":15386000,"period":"2017-12-31"},{"value":4515000,"period":"2017-12-31"},{"value":4275000,"period":"2017-09-30"},{"value":3509000,"period":"2017-06-30"},{"value":3087000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37414000,"rdSpendHistory":[{"period":"2025-12-31","value":37414000},{"period":"2024-12-31","value":37643000},{"period":"2023-12-31","value":40621000},{"period":"2022-12-31","value":63392000}],"sgaSpend":73652000,"operatingIncome":-3602000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-3602000},{"period":"2024-12-31","value":-42436000},{"period":"2023-12-31","value":-53292000},{"period":"2022-12-31","value":-79119000}],"netIncome":105895000,"netIncomeHistory":[{"period":"2025-12-31","value":105895000},{"period":"2024-12-31","value":-56418000},{"period":"2023-12-31","value":-55193000},{"period":"2022-12-31","value":872132000}],"eps":2.06,"epsHistory":[{"period":"2025-12-31","value":2.06},{"period":"2024-12-31","value":-1.15},{"period":"2023-12-31","value":-1},{"period":"2022-12-31","value":11.85}],"cash":167806000,"cashHistory":[{"period":"2025-12-31","value":167806000},{"period":"2024-12-31","value":37797000},{"period":"2023-12-31","value":39545000},{"period":"2022-12-31","value":298172000}],"totalAssets":485570000,"totalLiabilities":188847000,"totalDebt":42703000,"equity":296723000,"operatingCashflow":238541000,"operatingCashflowHistory":[{"period":"2025-12-31","value":238541000},{"period":"2024-12-31","value":-11535000},{"period":"2023-12-31","value":-26997000},{"period":"2022-12-31","value":-186991000}],"capex":-42000,"capexHistory":[{"period":"2025-12-31","value":-42000},{"period":"2024-12-31","value":-332000},{"period":"2023-12-31","value":-2488000},{"period":"2022-12-31","value":-572000}],"freeCashflow":238499000,"dividendsPaid":null,"buybacks":-4034000,"employees":90,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":18520000,"ebit":73650000,"ebitda":73846000,"period":"2025-12-31","revenue":45891000,"epsBasic":1.2,"netIncome":61024000,"rdExpense":7360000,"epsDiluted":1.15,"grossProfit":null,"operatingIncome":20011000},{"sga":18333000,"ebit":-2316000,"ebitda":-1680000,"period":"2025-09-30","revenue":19990000,"epsBasic":0.07,"netIncome":3615000,"rdExpense":8112000,"epsDiluted":0.07,"grossProfit":null,"operatingIncome":-6455000},{"sga":18430000,"ebit":73869000,"ebitda":74796000,"period":"2025-06-30","revenue":26195000,"epsBasic":1.09,"netIncome":54835000,"rdExpense":10490000,"epsDiluted":1.08,"grossProfit":null,"operatingIncome":-2725000},{"sga":18370000,"ebit":-13495000,"ebitda":-12443000,"period":"2025-03-31","revenue":15388000,"epsBasic":-0.27,"netIncome":-13579000,"rdExpense":11452000,"epsDiluted":-0.27,"grossProfit":null,"operatingIncome":-14434000},{"sga":18501000,"ebit":-8296000,"ebitda":-7601000,"period":"2024-12-31","revenue":18754000,"epsBasic":-0.31,"netIncome":-15527000,"rdExpense":9453000,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":-9200000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":16.62,"previousClose":16.67,"fiftyTwoWeekHigh":21.03,"fiftyTwoWeekLow":8.4,"fiftyTwoWeekRange":"8.4 - 21.03","fiftyDayAverage":15.71,"twoHundredDayAverage":16.17,"beta":0.19,"enterpriseValue":505226592,"forwardPE":12.3,"priceToBook":2.86,"priceToSales":7.81,"enterpriseToRevenue":4.6,"enterpriseToEbitda":76.83,"pegRatio":0,"ebitda":6576000,"ebitdaMargin":6,"freeCashflow":22506500,"operatingCashflow":268780992,"totalDebt":40504000,"debtToEquity":13.9,"currentRatio":13.14,"returnOnAssets":0.8,"returnOnEquity":50.2,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":17.2,"targetHighPrice":21,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":99.2,"sharesOutstanding":51553005,"floatShares":24585628,"sharesShort":5159991,"shortRatio":12.29,"shortPercentOfFloat":10,"epsTrailing":2.23,"epsForward":1.35,"revenuePerShare":2.17,"bookValue":5.81,"officers":[{"age":65,"name":"Mr. Rick E. Winningham M.B.A.","title":"CEO & Director"},{"age":60,"name":"Ms. Rhonda F. Farnum","title":"Chief Business Officer and Senior VP of Commercial & Medical Affairs"},{"age":48,"name":"Dr. Aine  Miller Ph.D.","title":"Senior VP of Development & Head of Ireland Office"},{"age":43,"name":"Mr. Aziz  Sawaf C.F.A.","title":"Senior VP & CFO"},{"age":null,"name":"Mr. Stuart  Knight","title":"Senior VP of IT&I and Chief Information Officer"},{"age":51,"name":"Mr. Brett A. Grimaud Esq.","title":"Senior VP, General Counsel & Secretary"},{"age":null,"name":"Ms. Stacy L. Pryce","title":"Senior VP & Chief Strategy Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.theravance.com","phone":"650 808 6000"}}